Nektar Therapeutics initiated with "outperform"

09/11/09 - Boenning & Scattergood

NEW YORK, September 11 (newratings.com) - Analysts at Boenning & Scattergood initiate coverage of Nektar Therapeutics (NKTR) with an "outperform" rating. The target price is set to $11.

In a research note published this morning, the analysts mention that the promising phase 2 data, related to the company’s lead proprietary drug candidate NKTR-118, positions it favourably in the opioinduced constipation market. Nektar Therapeutics is likely to enter into an economically favourable partnership in the near term, the analysts add.